The Pulmonary Fibrosis Foundation (PFF) say 1,000 people have enrolled on its PFF Patient Registry, an initiative to track data from PF patients nationwide. The registry will help researchers better understand pulmonary fibrosis by compiling data on disease progression, patient profiles and efficacy of available treatments. Enrollment is on track to…
News
Veracyte presented pivotal clinical validation data on the performance of its Envisia Genomic Classifier to diagnose idiopathic pulmonary fibrosis (IPF) at the American Thoracic Society (ATS) 2017 International Conference, held May 19-24 in Washington, D.C. IPF, a type of interstitial lung disease (ILD), is often challenging to diagnose. Each year, doctors in…
https://www.youtube.com/watch?v=dpUNgYbsQms If you have a chronic illness, you know just how much energy it takes to complete your daily chores and common household tasks. In this video from newlifeoutlook, Jennifer shares some practical tips to help make life a little easier for anyone suffering from a chronic illness. MORE: Nine tips…
Almost 37 percent of idiopathic pulmonary fibrosis patients who took Ofev for a year had no decline in a key measure of lung function, double the 18 percent of those on a placebo, according to one of three recent Ofev presentations in Washington. The results of that study applied to a…
Patients with idiopathic pulmonary fibrosis (IPF) want more information from their doctors at diagnosis, according to the results of a new survey. Researchers said that only half of patients surveyed report discussing antifibrotic treatment decisions with their doctors when they’re diagnosed. Results of the survey study, titled “Differences in…
Treatment with Genentech‘s FDA-approved Esbriet (pirfenidone) has been shown in two independent studies to improve moderate to more severe lung function impairment in patients with idiopathic pulmonary fibrosis (IPF). The results of the studies were recently presented at the American Thoracic Society International Conference (ATS 2017) May 19-24 in Washington,…
Prometic’s PBI-4050 leveled off idiopathic pulmonary fibrosis patients’ decline in lung function, indicating it is a promising treatment for the disease, according to a Phase 2 clinical trial. The leveling occurred when PBI-4050 was used by itself and when it was used in one of two combination therapies. IPF…
Bellerophon Therapeutics recently presented promising new data from two Phase 2 clinical trials investigating its product INOpulse in patients with pulmonary hypertension (PH) associated with idiopathic pulmonary fibrosis (IPF), and PH associated with chronic obstructive pulmonary disease (COPD) at the American Thoracic Society 113th International Conference (ATS 2017). The INOpulse device delivers inhaled nitric oxide…
Treatment with Galecto Biotech’s inhaled TD139 may become an effective and safe option for patients with idiopathic pulmonary fibrosis (IPF), according to a clinical trial conducted by Scotland’s University of Edinburgh. Galecto, a Danish pharmaceutical firm, will present the study’s findings at the American Thoracic Society 2017 International Conference…
The resokine protein reduced interstitial lung disease (ILD) in mice, according to one of two presentations that aTyr Pharma will make at the American Thoracic Society International Conference in Washington, which starts today. Atry derived its Resolaris therapy from resokine, which helps prevent the immune system from turning against healthy cells. Scientists…
